Bosentan for chronic thromboembolic pulmonary hypertension

References

• Fedullo PF, Auger WR, Kerr KM et al. Chronic thromboembolic pulmonary hypertension. N. Engl. J. Med.345, 1465–1472 (2001).
   PubMed Web of Science ®Google Scholar
• Deng Z, Morse JH, Slager SL et al. Familial primary pulmonary hypertension (gene PPH1 ) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am. J. Hum. Genet.67, 737–744 (2000).
   PubMed Web of Science ®Google Scholar
• Thomson JR, Machado RD, Pauciulo MW et al. Sporadic primary pulmonary hypertension is associated with germ line mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family. J. Med. Genet.37, 741–745 (2000).
   PubMed Web of Science ®Google Scholar
• Lang IM, Bonderman D, Jakowitsch J et al. Chronic thromboembolic pulmonary hypertension: update 2004. Eur. Respir. Mon.27, 243–252 (2003).
   Google Scholar
• Peacock AJ. Primary pulmonary hypertension. Thorax54, 1107–1118 (1999).
   PubMed Web of Science ®Google Scholar
• D’Alonzo GE, Bower JS, Dantzker DR. Differentiation of patients with primary and thromboembolic pulmonary hypertension. Chest85, 457–461 (1984).
   PubMed Web of Science ®Google Scholar
• Bonderman D, Wilkens H, Wakounig S et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur. Respir. J.33, 325–331 (2009).
   PubMed Web of Science ®Google Scholar
• Fedullo PF, Kerr KM, Auger WR et al. Chronic thromboembolic pulmonary hypertension. Semin. Respir. Crit. Care Med.21, 563–574 (2000).
   PubMed Web of Science ®Google Scholar
• Egermayer P, Peacock AJ. Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. Eur. Respir. J.15, 440–448 (2000).
   PubMed Web of Science ®Google Scholar
• Fedullo PF, Rubin LJ, Kerr KM et al. The natural history of acute and chronic thromboembolic disease: the searching for the missing link. Eur. Respir. J.15, 435–437(2000).
   PubMed Web of Science ®Google Scholar
• Lang IM. Chronic thromboembolic pulmonary hypertension: not so rare after all. N. Engl. J. Med.350, 2236–2238 (2004).
   PubMed Web of Science ®Google Scholar
• Pengo V, Lensing AW, Prins MH et al. ; Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N. Engl. J. Med.350, 2257–2264 (2004).
   PubMed Web of Science ®Google Scholar
• Becattini C, Agnelli G, Pesavento R et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episod of pulmonary embolism. Chest103, 172–175 (2006).
   Google Scholar
• Tapson VF, Humbert M. Incidence and prevalence of chronic thromboembolic pulmonary hypertension. From acute to chronic pulmonary embolism. Proc. Am. Thor. Soc.3, 564–567 (2006).
   PubMedGoogle Scholar
• Simonneau G, Robbins IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol.29, S43–S54 (2009).
   Google Scholar
• Riedel M, Stanek V, Widimsky J, Prerovsky I. Long-term follow-up of patients with pulmonary thromboembolism: late prognosis and evolution of hemodynamic and respiratory data. Chest81, 151–158 (1982).
   PubMed Web of Science ®Google Scholar
• Ribeiro A, Lindmarker P, Johnsson H et al. Pulmonary embolism: one-year follow-up with echocardiography Doppler and five-year survival analysis. Circulation99, 1325–1330 (1999).
   PubMed Web of Science ®Google Scholar
• Rubens FD, Bourke M, Hynes M et al. Surgery for chronic thromboembolic pulmonary hypertension: inclusive experience from a national referral center. Ann. Thorac. Surg.83, 1075–1081 (2007).
   PubMed Web of Science ®Google Scholar
• Jamieson SW, Kapelanski DP, Sakakibara N et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann. Thorac. Surg.76, 1457–1464 (2003).
   PubMed Web of Science ®Google Scholar
• Thistlethwaite PA Madani M, Jamieson SW. Outcomes of pulmonary endarterectomy surgery. Semin. Thorac. Cardiovasc. Surg.18, 257–264 (2003).
   Google Scholar
• D’Armini AM, Zanotti G, Pozzi M et al. Surgical treatment of chronic thromboembolic pulmonary hypertension with pulmonary endarterectomy. G. Ital. Cardiol.7(7), 454–463 (2006).
   Google Scholar
• Lewkzuc J, Pizsko P, Jagas J et al. Prognostic factors in medically treated patients with chronic pulmonary embolism. Chest119 (3), 818–823 (2001).
   PubMed Web of Science ®Google Scholar
• Ribeiro A, Lindmarker P, Johnsson H et al. Pulmonary embolism: one-year follow-up with echocardiography Doppler and five-year survival analysis. Circulation99, 1325–1330 (1999).
   PubMed Web of Science ®Google Scholar
• Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin. Pharmacokinet.43(15), 1089–1115 (2004).
   PubMed Web of Science ®Google Scholar
• Dingemanse J, van Giersbergen PL, Weidekamm E et al. Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin antagonist. J. Clin. Pharmacol.42(3), 283–289 (2002).
   PubMed Web of Science ®Google Scholar
• Dingemanse J, van Giersbergen PL. Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. Int. J. Clin. Pharmacol. Ther.40 (7), 310–316 (2002).
   PubMed Web of Science ®Google Scholar
• Goto K. Basic and therapeutic relevance of endothelin-mediated regulation. Biol. Pharm. Bull.24, 1219–1230 (2001).
   PubMed Web of Science ®Google Scholar
• Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin- 1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med.328, 1732–1739 (1993).
   PubMed Web of Science ®Google Scholar
• Rubens C, Ewert R, Halank M et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest120, 1562–1569 (2001).
   PubMed Web of Science ®Google Scholar
• Reesink HJ, Meijer RC, Lutter R et al. Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. Circ. J.70, 1058–1063 (2006).
   PubMed Web of Science ®Google Scholar
• Kim H, Yung GL, Marsh JJ et al. Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur. Respir. J.15, 640–648 (2000).
   PubMed Web of Science ®Google Scholar
• Bonderman D, Nowotny R, Skoro-Sajer N et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest128, 2599–2603 (2005).
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Kramm T, Wilkens H et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest128, 2363–2367 (2005).
   PubMed Web of Science ®Google Scholar
• Hughes R, George P, Parameshwar J et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension. Thorax60, 707 (2005).
   PubMed Web of Science ®Google Scholar
• Hughes RJ, Jais X, Bonderman D et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension: efficacy at 1 year. Eur. Respir. J.28, 138–143 (2006).
   PubMed Web of Science ®Google Scholar
• Seyfarth HJ, Hammerschmidt S, Pankau H et al. Long-term bosentan in chronic thromboembolic pulmonary hypertension. Respiration74, 287–292 (2007).
   PubMed Web of Science ®Google Scholar
• Segovia Cubero J, Ortiz Uribe JC, Gómez Bueno M et al. Role of bosentan in patients with chronic venous thromboembolic pulmonary hypertension. Med. Clin.128, 12–14 (2007).
   PubMed Web of Science ®Google Scholar
• Ulrich S, Speich R, Domenighetti G et al. Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of bosentan on hemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study). Swiss Med. Wkly137, 573–580 (2007).
   PubMed Web of Science ®Google Scholar
• Condliffe R, Kiely DG, Gibbs JSR et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care Med.177, 1122–1127 (2008).
   PubMed Web of Science ®Google Scholar
• Vassallo FG, Kodric M, Scarduelli C et al. Bosentan for patients with chronic thromboembolic pulmonary hypertension. Eur. J. Intern. Med.20, 24–29 (2009).
   PubMed Web of Science ®Google Scholar
• Reesink HJ, Sulaiman S, Kloek JJ et al. Bosentan as a bridge to pulmonary endoarterectomy for thromboembolic pulmonary hypertension. J. Thorac. Cardiovasc. Surg. DOI:10.1016/j.jtcvs.2009.03.053 (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Jaïs X, D’Armini AM, Jansa P et al. Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension Study Group. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension), a randomized, placebo-controlled trial. J. Am. Coll. Cardiol.52, 2127–2134 (2008).
   PubMed Web of Science ®Google Scholar
• Channick RN, Sitbon O, Barst RJ et al. Endothelin receptor antagonist in pulmonary arterial hypertension. J. Am. Coll. Cardiol.43, S62–S67 (2004).
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med.346, 896–903 (2002).
   PubMed Web of Science ®Google Scholar
• McLaughin VV, Hoeper MM. Pulmonary Arterial hypertension – the race for the most effective treatment. Am. J. Respir. Crit. Care Med.171, 1199–1201 (2005).
   PubMed Web of Science ®Google Scholar
• Spence S, Anderson C, Cukierski M et al. Teratogenic effects of the endothelin receptor antagonist L-753, 037 in the rat. Reprod. Toxicol.13, 15–29 (1999).
   PubMed Web of Science ®Google Scholar
• Weber C, Banken L, Birnboeck H, Schulz R. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J. Clin. Pharmacol.139, 847–854 (1999).
   Google Scholar
• Murphey LM, Hood EH. Bosentan and warfarin interaction. Ann. Pharmacother.37, 1028–1031 (2003).
   PubMed Web of Science ®Google Scholar
• Paul GA, Gibbs JS, Boobis AR et al. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br. J. Clin. Pharmacol.60, 107–112 (2005).
   PubMed Web of Science ®Google Scholar
• Humbert M, Segal ES, Kiely DG et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur. Respir. J.30(2), 338–344 (2007).
   PubMed Web of Science ®Google Scholar
• Carlsen J, Hoeper MM, Kiely DG et al. Long-term safety profile of bosentan in patients with chronic thromboembolic pulmonary hypertension (CTEPH): results from the TRAX database. Presented at: Annual Meeting of the European Society of Cardiology (ESC). Stockholm, Denmark, 3–7 September 2005 (abstract 763).
   Google Scholar
• Suntharalingham J, Hodgkins D, Cafferty FH et al. Does rapid dose titration affect the hepatic safety profile of bosentan? Vasc. Pharmacol.44, 508–512 (2006).
   PubMed Web of Science ®Google Scholar
• Beghetti M. Bosentan in pediatric patients with pulmonary arterial hypertension. Curr. Vasc. Pharmacol.7(2), 225–233 (2009).
   PubMed Web of Science ®Google Scholar
• Keogh AM, McNeil KD, Wlodarczyk J et al. Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J. Heart Lung Transplant.26(2), 181–187 (2007).
   PubMed Web of Science ®Google Scholar
• Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest103, 685–692 (1993).
   PubMed Web of Science ®Google Scholar
• Yi ES, Kim H, Ahn H, Strother J et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension: a morphometric and immunohistochemical study. Am. J. Respir. Crit. Care Med.162, 1577–1586 (2000).
   PubMed Web of Science ®Google Scholar
• Dartevelle P, Fadel E, Mussot S et al. Chronic thromboembolic pulmonary hypertension. Eur. Respir. J.23, 637– 648 (2004).
   PubMed Web of Science ®Google Scholar
• Peacock AJ, Naeije R, Galiè N, Rubin LJ. End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Eur. Respir. J.34, 231–242 (2009).
   PubMed Web of Science ®Google Scholar
• Bresser P, Pepke-Zaba J, Jais X et al. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. Proc. Am. Thor. Soc.3, 594–600 (2006).
   PubMedGoogle Scholar